Call for Papers - Chemotherapy-induced neurotoxicity

Guest Editors

Andreas A Argyriou, MD, PhD, General Hospital of Patras, Greece
David Balayssac, PhD, PharmD, Clermont Auvergne University, France

Submission Status: Open | Submission Deadline: 6 August 2025

This Collection seeks to gather research on chemotherapy-induced neurotoxicity, addressing its mechanisms, clinical impact, and potential neuroprotective strategies. We welcome submissions that explore the molecular pathways underlying neurotoxicity, the development of neuroprotective interventions, and the role of specific chemotherapeutic agents in neurotoxicity.

Submit to Collection

Meet the Guest Editors

Back to top

Andreas A Argyriou, MD, PhD, General Hospital of Patras, Greece

Dr Andreas A Argyriou, MD, PhD, serves as Neurology Medical Director and Senior Consultant Neurophysiologist at the Saint Andrew’s General Hospital of Patras, Greece. He is also specialist in Headache/Pain Medicine. He is Board Member (2018–present) in the Traumatic-Toxic Neuropathy Consortium of the Peripheral Nerve Society and coordinator of the corresponding Clinical Working Group. He is also Co-Chair (2020–present) of the chemotherapy-induced peripheral neurotoxicity (CIPN) subgroup of the Multinational Association of Supportive Care in Cancer (MASCC). Dr Argyriou authored more than 190 publications in international peer-reviewed journals, obtaining more than 6000 citations for those publications and h-index of 44.

David Balayssac, PhD, PharmD, Clermont Auvergne University, France

Prof David Balayssac is a teacher of Toxicology and Associate Dean of the Faculty of Pharmacy at Clermont Auvergne University, France. He is affiliated with the INSERM research unit Neuro-Dol (team: Fundamental and Clinical Pharmacology of Pain). He has been working for 20 years on chemotherapy-induced peripheral neuropathy (CIPN) in both animal models and patients with a translational research approach. His research explores 1) new pharmacological targets for the management of CIPN, 2) circulating biomarkers of CIPN, and 3) the long-term impact of CIPN and pain in cancer patients and survivors.

About the Collection

Chemotherapy-induced neurotoxicity is a common side effect of cancer treatment which can affect the nervous system. Platinum-based drugs, taxanes, bortezomib, and other cytotoxic chemotherapeutic agents are known culprits, often inducing peripheral neuropathy, central neurotoxicity, and ototoxicity and symptoms such as leukoencephalopathy, seizures, cerebral infarctions, and cognitive impairments, which significantly compromises patients' daily functioning. The impact on the central nervous system can also manifest as neurocognitive deficits, particularly evident in breast cancer survivors.

Understanding the mechanisms underlying chemotherapy-induced neurotoxicity and developing strategies for neuroprotection are critical areas of research in oncology. Recent advances have elucidated the molecular pathways involved in neurotoxicity, paving the way for the identification of potential neuroprotective agents and personalized treatment approaches.

With this in mind, this BMC Cancer Collection seeks research that elucidates the mechanisms driving chemotherapy-induced neurotoxicity, explores the nuances of peripheral neuropathy and central neurotoxicity, and proposes innovative neuroprotective approaches. Topics of interest include:

Peripheral neuropathy and central neurotoxicity
Mechanisms of chemotherapy-induced neurotoxicity
Preclinical models used to study neurotoxicity
Impact of combination chemotherapy regimens on neurotoxicity
Role of specific chemotherapeutic agents in neurotoxicity
Long-term neurocognitive effects of chemotherapy
Patient-reported outcomes and quality of life measures
Neuroprotective strategies for patients with cancer who receive chemotherapy

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Chemotherapy-induced neurotoxicity" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.